RE:RE:SOME Biogen chatterAs FDA decides on Biogen drug for Alzheimer’s, patients and families hold out hope By Jonathan Saltzman Globe Staff,Updated June 2, 2021, 52 minutes ago
Within days, federal regulators will decide whether to approve the first new drug for Alzheimer’s disease in nearly two decades, a controversial medicine from Cambridge-based Biogen that seems to have as many detractors as proponents.
It’s called aducanumab, and Kirsten Hano is among those hoping it wins approval.
A 1989 graduate of Williams College who lives in Wellesley, Hano once seemed able to do it all: work 10-hour days as an advertising executive; shepherd three sons to extracurricular activities; start a nonprofit group; and play ice hockey weekly with friends. But last November, after several years of finding it increasingly hard to complete routine tasks, she received a staggering diagnosis: early-onset Alzheimer’s.
https://www.bostonglobe.com/2021/06/02/business/fda-decides-biogen-drug-alzheimers-patients-families-hold-out-hope/